The EMPrint™ Ablate and RESect Study in Patients With Metastatic Lung Tumors

Overview

Información sobre este estudio

Post market prospective, non-randomized, single-arm, multicenter study, designed to demonstrate dose response of an ablation system using a percutaneous approach in patients with primary, metastatic, or recurrent primary lung tumors.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

  • Subject or authorized representative has provided informed consent.
  • Subject is ≥18 years of age.
  • At least one pulmonary metastasis ≤ 3.0 cm in maximum diameter resulting from distant primary cancers or at least one recurrence of primary lung cancer ≤ 3.0 cm in maximum diameter.
  • Subject has been confirmed by a thoracic surgeon to be a surgical candidate for resection of the tumor targeted for ablation.
  • Subject is willing and able to comply with all aspects of the treatment and evaluation schedule.
  • ≥1 cm of tumor-free lung parenchyma between target tumor and pleura or fissure.

Exclusion Criteria:

  • Pre-procedure Exclusion Criteria
  • Contraindicated for surgery.
  • Prolonged chest infection, defined as lung consolidation that requires hospitalization and greater than 10 days of antibiotics 30 days prior to surgery.
  • Tumor abutting main stem bronchus, main pulmonary artery branches, esophagus and/or trachea.
  • Tumor with pleural contact.
  • Tumors located < 3 cm of staple lines or other metal objects.
  • Patients diagnosed with GOLD Stage IV Emphysema.
  • Uncontrollable coagulopathy
  • Patients unable to tolerate discontinued use of anti-coagulants prior to and during the ablation procedure.
  • Subject is pregnant (documented by a positive pregnancy test according to hospital standard practices) or is actively breast-feeding.
  • Subject has participated in an investigational drug or device research study within 30 days of enrollment that would interfere with this study.
  • The investigator determines that participation in the study may jeopardize the safety or welfare of the subject.
  • Patients with implantable pacemakers and other electronic implants, in accordance with Instructions for Use (IFU).

Intraprocedural Exclusion Criteria

  • Incidental intraprocedural finding that the subject no longer meets the study eligibility criteria.

More information

Publicaciones

Publications are currently not available
.
CLS-20187340

Mayo Clinic Footer